Markers of Metabolism and Vascular Access in ESRD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2024-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the study is to determine the association of markers of mineral metabolism with vascular access out come (maturation, patency of vascular access\[AVF,AVG\])To verify the relationship between vascular access complication (AVF,AVG) and lower levels of 25(OH)D, higher levels of fibroblast growth factor 23 (FGF23) and serum calcium, phosphorus, parathyroid hormone (PTH) in patients with ESRD on regular hemodialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

NCT00237718

End-stage Renal Disease

COMPLETED PHASE2

Sclerostin and Vascular Calcification in CKD and Renal Transplant

NCT04066855

Vascular Calcification Chronic Kidney Failure

UNKNOWN

The Effect of Exercise on Blood Parameters Related to Dialysis Patients' Survival

NCT04916743

Chronic Kidney Diseases End Stage Renal Disease Hemodialysis

COMPLETED NA

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

NCT00477516

End-Stage Renal Disease

COMPLETED NA

Evaluation of Adherence to the Mediterranean Diet in Patients with Recurrent Renal Stones and Disease Osteometabolic

NCT06869603

Renal Stones Osteometabolic Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Maintaining patent vascular access is essential for patients with end-stage renal disease (ESRD) on hemodialysis (HD) to prevent life-threatening technique failure. Access complications result in a high burden of hospital admissions, procedures, and costs for patients on HD.

, The pathophysiologic mechanisms underlying vascular access complications are poorly understood. Discovery of potential predictors and subsequent targets for intervention could help design new preventive strategies.Abnormalities in mineral homeostasis are common in patients with ESRD and are associated with numerous adverse outcomes including vascular calcification, inflammation, and mortality.

The Klotho gene encodes for a transmembrane protein, acting as a co-receptor for fibroblast growth factor-23 (FGF23) . The main functions of FGF23 signaling in the kidney are the suppression of vitamin D hormone synthesis, and the suppression of renal tubular phosphate reabsorption .

Impaired excretion of phosphorus due to low kidney function raises fibroblast growth factor 23 (FGF23). FGF23 decreases conversion of 25-hydroxy vitamin D (25(OH)D) to its active 1,25D form, causing calcium to fall and parathyroid hormone(PTH) to rise The development of secondary hyperparathyroidism lead to increased calcium and phosphate release from bones to the blood, causing the deposition of calcium and phosphate in the intima-media layer of arterial wall. and eventuating vascular calcification in these patients. the calcifications might be encountered in the upper extremity arteries in cases with ESRD .Thus, a decrease in the quality of fistula occurs in these tracts utilized frequently at the arteriovenous fistula (AVF) operations. Thes complex interplay of factors may promote vascular disease through multiple pathways including calcification, endothelial dysfunction, inflammation, activation of the renin-angiotensin-aldosterone system and others are involved. Deficiency of 25(OH)D among patients with ESRD is above 80%.1,25D or its analogs are frequently administered to patients with ESRD to overcome the adverse effects. low 25(OH)D associates with mortality in HD patients.

Vitamin D deficiency has been associated with hypertension, insulin resistance, viral and bacterial infection risk, and multiple organ damage due to systemic inflammation.

Despite consistent associations of disordered mineral homeostasis and vascular outcomes in ESRD, few studies have investigated the role of these factors in vascular access out comes

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorders of Calcium and Bone Metabolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vascular acess

AVF

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patient above the age of 18years old.
2. patient on regular hemodialysis with vascular access(AVF,AVG)
3. patient with Abnormalities in mineral metabolisms.
4. Patient secondary, Tertiary hyperparathyroidism.